Find an expert
Our panel of editors are available for interview
Professor Ronald F. van Vollenhoven
Editor-in-Chief of Lupus Science & Medicine
Professor Ronald F. van Vollenhoven is a distinguished rheumatologist and immunologist, known for his significant contributions in the field. He currently holds the position of Chair of the Department of Rheumatology and Clinical Immunology at Amsterdam UMC and directs the Amsterdam Rheumatology Centre. With a background in immunology and extensive training in Internal Medicine and Rheumatology, he has dedicated his career to the development and evaluation of biological and immunomodulatory treatments for rheumatic diseases. Dr. Van Vollenhoven has played a pivotal role in establishing crucial registries, including the Stockholm registry for biological therapies (STURE database), and has been a principal investigator in numerous clinical trials.
Dr James Mountford
Editor-in-Chief of BMJ Leader
Dr James Mountford is Director of Quality at Royal Free London NHS Foundation Trust. He worked initially as an NHS doctor, then in consulting. From 2005-2007, he was a Commonwealth Fund Health Foundation Harkness Fellow based in Massachusetts General Hospital, and at the Institute for Healthcare Improvement (IHI), both in Boston, USA. Before moving to the Royal Free, he was Director of Quality at UCL Partners, an academic health sciences partnership serving a population of 3 million in and around London. He sits on the board of AQuA, the improvement partnership based in north-west England. In March 2020 he was seconded to work as the Chief of Quality and Learning at the NHS Nightingale Hospital London, opened in response to the COVID-19 pandemic.
Professor Bryony Dean Franklin
Editor-in-Chief of BMJ Quality & Safety
Professor Bryony Dean Franklin is a hospital pharmacist by background, with 30 years’ experience of research into medication safety, medication use in practice and patient safety more generally. She is Co-Editor-in-Chief of BMJ Quality & Safety, Professor of Medication Safety at UCL School of Pharmacy, Executive Lead Pharmacist for Research at Imperial College Healthcare NHS Trust, Director of the NIHR North West London Patient Safety Research Collaboration and theme lead for the NIHR Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance at Imperial College London. Professor Franklin has published widely on medication safety, the evaluation of various technologies designed to reduce errors, and the patient’s role in patient safety. Her current post combines research, quality improvement, education and training, medical publishing and hospital pharmacy practice.
Shanti Raman
Editor-in-Chief of BMJ Paediatrics Open
Shanti Raman is a Consultant Paediatrician, with sub-specialty training in Community Child Health, epidemiology and public health. She is the Director of Community Paediatrics – South Western
Sydney, where she is responsible for clinical services in Child Development and Child Protection across the region, providing academic leadership and directing research and training. Her research
and teaching interests include health of migrants and refugees, indigenous child health, child rights and child maltreatment, quality and safety in health, global maternal, newborn and child health.
Theodora Bloom
Executive Editor of the BMJ
Theodora Bloom is executive editor of The BMJ. At the BMJ, Theo’s responsibilities include publishing, business, platform and operations as well as ethical and policy matters. She is a Co-Founder of the medRxiv preprint server, a collaboration between BMJ, Cold Spring Harbor Laboratory and Yale University, and jointly coordinates open access and open research initiatives at BMJ.
Professor Ganesan Karthikeyan
Editor-in-Chief Open Heart
Professor Karthikeyan is a clinical, interventional cardiologist and a Senior International Fellow of the Population Health Research Institute at McMaster University in Canada, as well as Professor of Cardiology at AIIMS. His research is mainly focused on cardiovascular diseases affecting low and middle income countries, including valvular heart disease, particularly rheumatic heart disease (RHD), mechanical valve thrombosis, anticoagulation, and indigenous drug-eluting stents.
